Articoli di riviste sul tema "STAT inhibitors"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "STAT inhibitors".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.
Ebersbach, Celina, Alicia-Marie K. Beier, Christian Thomas e Holger H. H. Erb. "Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer". Cancers 13, n. 19 (28 settembre 2021): 4854. http://dx.doi.org/10.3390/cancers13194854.
Lee, Hyun-Ku, Gita Singh e Sujay Singh. "STAT reporter cell line systems as a tool for cancer therapeutic target screening." Journal of Immunology 200, n. 1_Supplement (1 maggio 2018): 169.8. http://dx.doi.org/10.4049/jimmunol.200.supp.169.8.
Jones, Dan, Justin Windham, Brian Stewart, Luis Fayad, Alma Rodriguez e Fredrick B. Hagemeister. "Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors." Blood 114, n. 22 (20 novembre 2009): 968. http://dx.doi.org/10.1182/blood.v114.22.968.968.
Standing, David, Emma Feess, Satvik Kodiyalam, Michael Kuehn, Zachary Hamel, Jaimie Johnson, Sufi Mary Thomas e Shrikant Anant. "The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy". Cancers 15, n. 9 (26 aprile 2023): 2485. http://dx.doi.org/10.3390/cancers15092485.
Rodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, John Weroha e John Hawse. "Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target". Cancer Research 82, n. 12_Supplement (15 giugno 2022): 1129. http://dx.doi.org/10.1158/1538-7445.am2022-1129.
Zhou, Jianbiao, Chonglei Bi, Lai Fong Poon, Viraj J. Janakakumara, Jiaying Khng, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Davidsen K. Davidsen e Chien-Shing Chen. "Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML." Blood 110, n. 11 (16 novembre 2007): 2367. http://dx.doi.org/10.1182/blood.v110.11.2367.2367.
Suzuki, Asuka, Toshikatsu Hanada, Keiichi Mitsuyama, Takafumi Yoshida, Shintaro Kamizono, Tomoaki Hoshino, Masato Kubo et al. "Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation". Journal of Experimental Medicine 193, n. 4 (12 febbraio 2001): 471–82. http://dx.doi.org/10.1084/jem.193.4.471.
Galli Sanchez, Ana Paula, Tatiane Ester Aidar Fernandes e Gustavo Martelli Palomino. "The JAK-STAT Pathway and the JAK Inhibitors". Journal of Clinical Research in Dermatology 7, n. 5 (30 novembre 2020): 1–6. http://dx.doi.org/10.15226/2378-1726/7/5/001128.
Wang, Weiyuan, Melanie Cristina Lopez McDonald, Rajashree Hariprasad, Tiara Hamilton e David A. Frank. "Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation". Cancers 16, n. 7 (31 marzo 2024): 1387. http://dx.doi.org/10.3390/cancers16071387.
Hu, Cheng-Ping, Jun-Tao Feng, Yu-Ling Tang, Jin-Qi Zhu, Min-Juan Lin e Ming-En Yu. "LIF Upregulates Expression of NK-1R in NHBE Cells". Mediators of Inflammation 2006 (2006): 1–8. http://dx.doi.org/10.1155/mi/2006/84829.
Tolomeo, Manlio, Maria Meli e Stefania Grimaudo. "STAT5 and STAT5 Inhibitors in Hematological Malignancies". Anti-Cancer Agents in Medicinal Chemistry 19, n. 17 (24 gennaio 2020): 2036–46. http://dx.doi.org/10.2174/1871520619666190906160848.
Orlova, Anna, Christina Wagner, Elvin D. de Araujo, Dávid Bajusz, Heidi A. Neubauer, Marco Herling, Patrick T. Gunning, György M. Keserű e Richard Moriggl. "Direct Targeting Options for STAT3 and STAT5 in Cancer". Cancers 11, n. 12 (3 dicembre 2019): 1930. http://dx.doi.org/10.3390/cancers11121930.
Zhou, Jianbiao, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon et al. "Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML". Blood 113, n. 17 (23 aprile 2009): 4052–62. http://dx.doi.org/10.1182/blood-2008-05-156422.
Haysen, S., A. L. L. Nielsen, P. Qvist e T. W. Kragstrup. "POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23 maggio 2022): 234.1–234. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2593.
Zhang, Xuekang, Jun Zhou, Qian Hu, Zhengren Liu, Qiuhong Chen, Wenxiang Wang, Huaigen Zhang, Qin Zhang e Yuanlu Huang. "The Role of Janus Kinase/Signal Transducer and Activator of Transcription Signalling on Preventing Intestinal Ischemia/Reperfusion Injury with Dexmedetomidine". Journal of Nanoscience and Nanotechnology 20, n. 5 (1 maggio 2020): 3295–302. http://dx.doi.org/10.1166/jnn.2020.16416.
Moser, Bernhard, Sophie Edtmayer, Agnieszka Witalisz-Siepracka e Dagmar Stoiber. "The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia". Biomedicines 9, n. 8 (19 agosto 2021): 1051. http://dx.doi.org/10.3390/biomedicines9081051.
Brachet-Botineau, Marie, Marion Polomski, Heidi A. Neubauer, Ludovic Juen, Damien Hédou, Marie-Claude Viaud-Massuard, Gildas Prié e Fabrice Gouilleux. "Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers". Cancers 12, n. 1 (18 gennaio 2020): 240. http://dx.doi.org/10.3390/cancers12010240.
Kitanaga, Yukihiro, Emiko Imamura, Yutaka Nakahara, Hidehiko Fukahori, Yasutomo Fujii, Satoshi Kubo, Shingo Nakayamada e Yoshiya Tanaka. "In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors". Rheumatology 59, n. 8 (25 novembre 2019): 1957–68. http://dx.doi.org/10.1093/rheumatology/kez526.
Rodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, Scott Kaufmann, Saravut J. Weroha e John Hawse. "Abstract 4862: Investigation of the JAK/STAT signaling pathway in chemotherapy and PARP inhibitor resistant ovarian cancer". Cancer Research 83, n. 7_Supplement (4 aprile 2023): 4862. http://dx.doi.org/10.1158/1538-7445.am2023-4862.
Rodman, Esther, Michael Emch, Archit Bajaj, Xiaojia Tang, Xiaonan Hou, Scott Kaufmann, Krishna Kalari, John Weroha e John Hawse. "Abstract B002: Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer". Cancer Research 84, n. 5_Supplement_2 (4 marzo 2024): B002. http://dx.doi.org/10.1158/1538-7445.ovarian23-b002.
Liang, Zengenni, Zhi-Hang Yuan, Yan Wang, Zhong-Hua Du, Jia-Jing Guo, Ling-Li Xia e Yang Shan. "New Mechanistic Insight into the Protective Effects of Ganoderma lucidum Polysaccharides Against Palmitic Acid-Induced Cell Damage in Porcine Intestinal Epithelial Cell Line IPEC-J2". Natural Product Communications 17, n. 11 (novembre 2022): 1934578X2211281. http://dx.doi.org/10.1177/1934578x221128103.
Komyod, Waraporn, Uta-Maria Bauer, Peter C. Heinrich, Serge Haan e Iris Behrmann. "Are STATS Arginine-methylated?" Journal of Biological Chemistry 280, n. 23 (12 aprile 2005): 21700–21705. http://dx.doi.org/10.1074/jbc.c400606200.
Callus, Bernard A., e Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n. 9 (1 maggio 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.
Callus, Bernard A., e Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n. 9 (1 maggio 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.3182_3182_3192.
Kuusanmäki, Heikki, Hanna Rajala, Arjan van Adrichem, Muntasir Mamun Majumder, Emma I. Andersson, Krister Wennerberg, Satu Mustjoki e Caroline A. Heckman. "Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies". Blood 124, n. 21 (6 dicembre 2014): 1771. http://dx.doi.org/10.1182/blood.v124.21.1771.1771.
Ozawa, Yukiyasu, Ann H. Williams, Myka Estes, Lubomir Sokol, Richard Jove e Alan F. List. "Regulation of Signal Transducers and Activators of Transcription by Src Family Kinase in AML." Blood 106, n. 11 (16 novembre 2005): 2766. http://dx.doi.org/10.1182/blood.v106.11.2766.2766.
Song, Tammy Linlin, Maarja-Liisa Nairismägi, Yurike Laurensia, Jing-Quan Lim, Jing Tan, Zhi-Mei Li, Wan-Lu Pang et al. "Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma". Blood 132, n. 11 (13 settembre 2018): 1146–58. http://dx.doi.org/10.1182/blood-2018-01-829424.
Jang, Sun Hee, e Ji Hyeon Ju. "Janus kinase inhibitors for the treatment of rheumatoid arthritis". Journal of the Korean Medical Association 64, n. 2 (10 febbraio 2021): 105–8. http://dx.doi.org/10.5124/jkma.2021.64.2.105.
Banes, Amy K., Séan Shaw, John Jenkins, Heather Redd, Farhad Amiri, David M. Pollock e Mario B. Marrero. "Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli". American Journal of Physiology-Renal Physiology 286, n. 4 (aprile 2004): F653—F659. http://dx.doi.org/10.1152/ajprenal.00163.2003.
Thomas, Sally J., Katherine Fisher, Stephen Brown, John A. Snowden, Sarah Danson e Martin Zeidler. "Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling". Blood 124, n. 21 (6 dicembre 2014): 4577. http://dx.doi.org/10.1182/blood.v124.21.4577.4577.
Severin, Frezzato, Visentin, Martini, Trimarco, Carraro, Tibaldi et al. "In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment". Cancers 11, n. 12 (4 dicembre 2019): 1939. http://dx.doi.org/10.3390/cancers11121939.
LEJEUNE, Diane, Jean-Baptiste DEMOULIN e Jean-Christophe RENAULD. "Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling". Biochemical Journal 353, n. 1 (18 dicembre 2000): 109–16. http://dx.doi.org/10.1042/bj3530109.
Malemud, Charles J. "The role of the JAK/STAT signal pathway in rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease 10, n. 5-6 (19 maggio 2018): 117–27. http://dx.doi.org/10.1177/1759720x18776224.
Hindupur, Sruthi V., Sebastian C. Schmid, Jana Annika Koch, Ahmed Youssef, Eva-Maria Baur, Dongbiao Wang, Thomas Horn et al. "STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy". International Journal of Molecular Sciences 21, n. 3 (7 febbraio 2020): 1106. http://dx.doi.org/10.3390/ijms21031106.
Jeong, Ga Hee, e Ji Hyun Lee. "Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies". International Journal of Molecular Sciences 24, n. 24 (10 dicembre 2023): 17322. http://dx.doi.org/10.3390/ijms242417322.
Kim, Lee, Song, Park, Gadhe, Choi, Lee, Pae, Kim e Ye. "Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy". Journal of Clinical Medicine 8, n. 11 (2 novembre 2019): 1847. http://dx.doi.org/10.3390/jcm8111847.
Demosthenous, Christos, Guangzhen Hu, Thomas E. Witzig e Mamta Gupta. "Loss-of-Function Missense Mutations in Tyrosine Phosphatase PTPN6 Deregulate STAT3 Signaling in Diffuse Large B-Cell Lymphoma". Blood 124, n. 21 (6 dicembre 2014): 707. http://dx.doi.org/10.1182/blood.v124.21.707.707.
Koppikar, Priya, Omar Abdel-Wahab, Cyrus Hedvat, Sachie Marubayashi, Jay Patel, Aviva Goel, Nicole Kucine et al. "Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis". Blood 115, n. 14 (8 aprile 2010): 2919–27. http://dx.doi.org/10.1182/blood-2009-04-218842.
Cacciapaglia, F., S. Perniola, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, M. Fornaro e F. Iannone. "AB0134 IN-VITRO STUDY ON THE EFFECT OF SELECTIVE Jak-INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 maggio 2022): 1196.3–1197. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2625.
Cacciapaglia, F., V. Venerito, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, N. Lacarpia, M. Fornaro e F. Iannone. "AB0070 INHIBITION OF STAT3 IN PBMCs FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 maggio 2022): 1167.2–1168. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1997.
Kapuria, Vaibhav, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz e Nicholas Donato. "A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling." Blood 110, n. 11 (16 novembre 2007): 1556. http://dx.doi.org/10.1182/blood.v110.11.1556.1556.
Ma, Frank Y., Greg M. Anderson, Travis D. Gunn, Vincent Goffin, David R. Grattan e Stephen J. Bunn. "Prolactin Specifically Activates Signal Transducer and Activator of Transcription 5b in Neuroendocrine Dopaminergic Neurons". Endocrinology 146, n. 12 (1 dicembre 2005): 5112–19. http://dx.doi.org/10.1210/en.2005-0770.
Aue, Arman, Franziska Szelinski, Sarah Y. Weißenberg, Annika Wiedemann, Thomas Rose, Andreia C. Lino e Thomas Dörner. "Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility". Rheumatology 59, n. 11 (1 maggio 2020): 3435–42. http://dx.doi.org/10.1093/rheumatology/keaa187.
Nelson, Erik A., Sarah R. Walker, Alicia Kepich, Shariya Terrell, Laurie Gashin e David A. Frank. "Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells." Blood 110, n. 11 (16 novembre 2007): 2953. http://dx.doi.org/10.1182/blood.v110.11.2953.2953.
Simon, Amy R., Satoe Takahashi, Mariano Severgnini, Barry L. Fanburg e Brent H. Cochran. "Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 282, n. 6 (1 giugno 2002): L1296—L1304. http://dx.doi.org/10.1152/ajplung.00315.2001.
Verdeil, Grégory, Toby Lawrence, Anne-Marie Schmitt-Verhulst e Nathalie Auphan-Anezin. "Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy". Cancers 11, n. 12 (21 novembre 2019): 1832. http://dx.doi.org/10.3390/cancers11121832.
Tian, Q., H. R. Wang, M. Z. Wang, C. Wang e S. M. Liu. "Lactogenic hormones regulate mammary protein synthesis in bovine mammary epithelial cells via the mTOR and JAK–STAT signal pathways". Animal Production Science 56, n. 11 (2016): 1803. http://dx.doi.org/10.1071/an14113.
Schwartz, Daniella M., Aran Son, Francoise Meylan, Julio Gomez-Rodriguez, Zenia Kaul, McKella Sylvester, Moses Kitakule et al. "Dynamic chromatin accessibility licenses STAT5- and STAT6-dependent innate-like function of Th9 cells to promote allergic inflammation". Journal of Immunology 210, n. 1_Supplement (1 maggio 2023): 67.21. http://dx.doi.org/10.4049/jimmunol.210.supp.67.21.
Zong, Hongliang, Tony Taldone, Gail J. Roboz, Gabriela Chiosis e Monica L. Guzman. "A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML". Blood 126, n. 23 (3 dicembre 2015): 2567. http://dx.doi.org/10.1182/blood.v126.23.2567.2567.
Furqan, Muhammad, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen e Delong Liu. "STAT inhibitors for cancer therapy". Journal of Hematology & Oncology 6, n. 1 (2013): 90. http://dx.doi.org/10.1186/1756-8722-6-90.